每經AI快訊，有投(tou)資者(zhe)在投(tou)資者(zhe)互動平臺提問：董秘(mi)您好，關于新品上市被稱為（心衰界的新寵）可溶性(xing)生長刺(ci)激表達基(ji)因(yin)2蛋白，真是可喜可賀，請問對今后公司業績影(ying)響幾何，另外中標江西省多個品類金額(e)排(pai)名第一是否屬(shu)實，謝謝

美康(kang)生(sheng)物(wu)（300439.SZ）7月(yue)8日在投資者互動平臺表示，可溶(rong)性(xing)生(sheng)長(chang)刺(ci)(ci)激(ji)表達(da)基因2蛋白檢(jian)測試(shi)(shi)劑(ji)盒(he)用(yong)于(yu)體(ti)外定性(xing)測定人血(xue)(xue)清或血(xue)(xue)漿的(de)(de)可溶(rong)性(xing)生(sheng)長(chang)刺(ci)(ci)激(ji)表達(da)基因2蛋白（ST2）濃度，是(shi)新一(yi)(yi)代(dai)的(de)(de)心(xin)(xin)(xin)(xin)衰(shuai)(shuai)標志物(wu)，適(shi)用(yong)于(yu)急性(xing)和(he)慢性(xing)心(xin)(xin)(xin)(xin)力衰(shuai)(shuai)竭、心(xin)(xin)(xin)(xin)肌梗(geng)死、心(xin)(xin)(xin)(xin)肌纖維(wei)化(hua)及(ji)(ji)心(xin)(xin)(xin)(xin)血(xue)(xue)管(guan)病等高風險人群的(de)(de)指導治療(liao)和(he)預(yu)后評(ping)估(gu)。該產品(pin)(pin)實際銷售(shou)情況取決于(yu)未(wei)來市場推廣效(xiao)果，公(gong)(gong)(gong)司(si)目前尚無法預(yu)測其對公(gong)(gong)(gong)司(si)未(wei)來業(ye)績(ji)的(de)(de)影響。 在江西(xi)牽(qian)頭的(de)(de)生(sheng)化(hua)試(shi)(shi)劑(ji)集采(cai)中(zhong)(zhong)(zhong)(zhong)，公(gong)(gong)(gong)司(si)中(zhong)(zhong)(zhong)(zhong)標項(xiang)目品(pin)(pin)規(gui)數(shu)最(zui)全，并非金額排名(ming)第(di)一(yi)(yi)。其中(zhong)(zhong)(zhong)(zhong)，2022年末(mo)(mo)的(de)(de)23省肝功類生(sheng)化(hua)檢(jian)測試(shi)(shi)劑(ji)省際聯盟集中(zhong)(zhong)(zhong)(zhong)帶(dai)量采(cai)購，公(gong)(gong)(gong)司(si)共(gong)中(zhong)(zhong)(zhong)(zhong)選25個項(xiang)目的(de)(de)50個品(pin)(pin)規(gui)，毫(hao)升及(ji)(ji)人份規(gui)格(ge)全部(bu)中(zhong)(zhong)(zhong)(zhong)選，中(zhong)(zhong)(zhong)(zhong)選項(xiang)目數(shu)和(he)中(zhong)(zhong)(zhong)(zhong)選品(pin)(pin)規(gui)數(shu)在此次(ci)參加的(de)(de)廠(chang)家(jia)中(zhong)(zhong)(zhong)(zhong)位(wei)列第(di)一(yi)(yi)。2023年末(mo)(mo)的(de)(de)腎功和(he)心(xin)(xin)(xin)(xin)肌酶生(sheng)化(hua)類檢(jian)測試(shi)(shi)劑(ji)省際聯盟集中(zhong)(zhong)(zhong)(zhong)帶(dai)量，公(gong)(gong)(gong)司(si)共(gong)中(zhong)(zhong)(zhong)(zhong)選27個項(xiang)目，54個品(pin)(pin)規(gui)，毫(hao)升及(ji)(ji)人份規(gui)格(ge)全部(bu)中(zhong)(zhong)(zhong)(zhong)選A組，成(cheng)為此次(ci)帶(dai)量采(cai)購中(zhong)(zhong)(zhong)(zhong)選品(pin)(pin)規(gui)最(zui)多的(de)(de)廠(chang)家(jia)。

(記者 蔡鼎)

免責(ze)聲明：本文內容與(yu)數據僅供(gong)參考，不構成投資建議，使用(yong)前核實。據此操作，風(feng)險自擔。